Tags

Type your tag names separated by a space and hit enter

Drug delivery to paranasal sinuses using pulsating aerosols.
J Aerosol Med Pulm Drug Deliv. 2014 Aug; 27(4):255-63.JA

Abstract

Chronic rhinosinusitis (CRS) is the major disorder of the upper airways, affecting about 10-15% of the total population. Topical treatment regimens show only modest efficacy, because drug delivery to the posterior nose and paranasal sinuses is still a challenge. Therefore, there is a high rate of functional endoscopic sinus surgery in CRS patients. Most nasally administered aerosolized drugs, like nasal pump sprays, are efficiently filtered by the nasal valve and do not reach the posterior nasal cavity and the sinuses, which are poorly ventilated. However, as highlighted in this review, sinus ventilation and paranasal aerosol delivery can be achieved by using pulsating airflow, offering new topical treatment options for nasal disorders. Radioaerosol inhalation and imaging studies in nasal casts and in healthy volunteers have shown 4-6% of the nasally administered dose within the sinuses. In CRS patients, significant aerosol deposition in the sinus cavities was reported before sinus surgery. After surgery, deposition increased to the amount observed in healthy volunteers. In addition, compared with nasal pump sprays, retention kinetics of the radiolabel deposited in the nasal cavity was prolonged, both in healthy volunteers and in CRS patients. These efficiencies may be sufficient for topical aerosol therapies of sinus disorders and, due to the prolonged retention kinetics, may reduce application modes, but have to be proven in future clinical trials. Pulsating aerosols may offer additional new topical treatment options of nasal and sinus disorders before as well as after surgery.

Links

Publisher Full Text (DOI)

Authors+Show Affiliations

Möller W
1 Comprehensive Pneumology Center, Institute for Lung Biology and Disease , Helmholtz Zentrum München, Neuherberg, Germany .
Schuschnig U
No affiliation info available
Bartenstein P
No affiliation info available
Meyer G
No affiliation info available
Häussinger K
No affiliation info available
Schmid O
No affiliation info available
Becker S
No affiliation info available

MeSH

AcousticsAdministration, IntranasalAerosolsChemistry, PharmaceuticalChronic DiseaseDrug Delivery SystemsEquipment DesignHumansMotionParanasal SinusesPharmaceutical PreparationsPharmacokineticsRhinitisSinusitisSound

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't
Review

Language

eng

PubMed ID

25084017

Citation

Möller, Winfried, et al. "Drug Delivery to Paranasal Sinuses Using Pulsating Aerosols." Journal of Aerosol Medicine and Pulmonary Drug Delivery, vol. 27, no. 4, 2014, pp. 255-63.
Möller W, Schuschnig U, Bartenstein P, et al. Drug delivery to paranasal sinuses using pulsating aerosols. J Aerosol Med Pulm Drug Deliv. 2014;27(4):255-63.
Möller, W., Schuschnig, U., Bartenstein, P., Meyer, G., Häussinger, K., Schmid, O., & Becker, S. (2014). Drug delivery to paranasal sinuses using pulsating aerosols. Journal of Aerosol Medicine and Pulmonary Drug Delivery, 27(4), 255-63. https://doi.org/10.1089/jamp.2013.1071
Möller W, et al. Drug Delivery to Paranasal Sinuses Using Pulsating Aerosols. J Aerosol Med Pulm Drug Deliv. 2014;27(4):255-63. PubMed PMID: 25084017.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Drug delivery to paranasal sinuses using pulsating aerosols. AU - Möller,Winfried, AU - Schuschnig,Uwe, AU - Bartenstein,Peter, AU - Meyer,Gabriele, AU - Häussinger,Karl, AU - Schmid,Otmar, AU - Becker,Sven, PY - 2014/8/2/entrez PY - 2014/8/2/pubmed PY - 2015/4/14/medline KW - chronic rhinosinusitis KW - clearance KW - paranasal sinus ventilation KW - pulsating aerosol KW - topical therapy SP - 255 EP - 63 JF - Journal of aerosol medicine and pulmonary drug delivery JO - J Aerosol Med Pulm Drug Deliv VL - 27 IS - 4 N2 - Chronic rhinosinusitis (CRS) is the major disorder of the upper airways, affecting about 10-15% of the total population. Topical treatment regimens show only modest efficacy, because drug delivery to the posterior nose and paranasal sinuses is still a challenge. Therefore, there is a high rate of functional endoscopic sinus surgery in CRS patients. Most nasally administered aerosolized drugs, like nasal pump sprays, are efficiently filtered by the nasal valve and do not reach the posterior nasal cavity and the sinuses, which are poorly ventilated. However, as highlighted in this review, sinus ventilation and paranasal aerosol delivery can be achieved by using pulsating airflow, offering new topical treatment options for nasal disorders. Radioaerosol inhalation and imaging studies in nasal casts and in healthy volunteers have shown 4-6% of the nasally administered dose within the sinuses. In CRS patients, significant aerosol deposition in the sinus cavities was reported before sinus surgery. After surgery, deposition increased to the amount observed in healthy volunteers. In addition, compared with nasal pump sprays, retention kinetics of the radiolabel deposited in the nasal cavity was prolonged, both in healthy volunteers and in CRS patients. These efficiencies may be sufficient for topical aerosol therapies of sinus disorders and, due to the prolonged retention kinetics, may reduce application modes, but have to be proven in future clinical trials. Pulsating aerosols may offer additional new topical treatment options of nasal and sinus disorders before as well as after surgery. SN - 1941-2703 UR - https://www.unboundmedicine.com/medline/citation/25084017/Drug_delivery_to_paranasal_sinuses_using_pulsating_aerosols_ DB - PRIME DP - Unbound Medicine ER -